ArticleNeuropsychiatric disease and treatment2011

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands.

Bart Hoogveldt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.